Ernexa Therapeutics
ERNA----
About
Ernexa Therapeutics
ERNA.US
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc.
Profile
- Company Name
- Ernexa Therapeutics Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- December 31
- Website
- www.ernexatx.com